Expert Opinion on Investigational Drugs, Volume 30, Issue 9 (2021)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 30, Issue 9 (2021)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Volume 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Drug Evaluation

Article
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas
Susan Dababou, Simone Garzon, Antonio Simone Laganà, Simone Ferrero, Giulio Evangelisti, Marco Noventa, Maurizio Nicola D’Alterio, Stefano Palomba, Stefano Uccella, Massimo Franchi & Fabio Barra
Pages: 903-911
Published online: 04 Aug 2021
AbstractforLinzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas | Full Text | References | PDF (451.3 KB) | EPUB
  • 838 Views
  • 20 CrossRef citations
  • 0Altmetric
Article
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer
Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Mario Miccoli, Maria Rosaria Galdiero, Gilda Varricchi, Rudy Foddis, Giovanni Guglielmi, Claudio Spinelli, Concettina La Motta, Salvatore Benvenga, Alessandro Antonelli & Poupak Fallahi
Pages: 913-921
Published online: 06 Sep 2021
AbstractforLenvatinib: an investigational agent for the treatment of differentiated thyroid cancer | Full Text | References | PDF (361.3 KB) | EPUB
  • 246 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis
Jia Li, Xiaoshuai Wang, Guangfeng Ruan, Zhaohua Zhu & Changhai Ding
Pages: 923-930
Published online: 03 Sep 2021
AbstractforSprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis | Full Text | References | PDF (1.2 MB) | EPUB
  • 581 Views
  • 9 CrossRef citations
  • 0Altmetric

Review

Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development
Berta Caballol, Victoria Gudiño, Julian Panes & Azucena Salas
Pages: 931-946
Published online: 10 Aug 2021
AbstractforUlcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development | Full Text | References | PDF (2 MB) | EPUB
  • 837 Views
  • 4 CrossRef citations
  • 0Altmetric
Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches
Bharat Narasimhan, Harish Narasimhan, Marta Lorente-Ros, Francisco Jose Romeo, Kirtipal Bhatia & Wilbert S. Aronow
Pages: 947-963
Published online: 13 Aug 2021
AbstractforTherapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches | Full Text | References | PDF (1.7 MB) | EPUB
  • 362 Views
  • 5 CrossRef citations
  • 0Altmetric
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options
Baptiste Le Calvez, Philippe Moreau & Cyrille Touzeau
Pages: 965-973
Published online: 19 Jul 2021
AbstractforImmune checkpoint inhibitors for the treatment of myeloma: novel investigational options | Full Text | References | PDF (1.1 MB) | EPUB
  • 462 Views
  • 6 CrossRef citations
  • 0Altmetric
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials
Héloïse Bourien, Angela Lamarca, Mairéad G McNamara, Richard A Hubner, Juan W Valle & Julien Edeline
Pages: 975-983
Published online: 22 Aug 2021
AbstractforDruggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials | Full Text | References | PDF (2.1 MB) | EPUB
  • 257 Views
  • 4 CrossRef citations
  • 0Altmetric
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma
Watcharin Loilome, Hasaya Dokduang, Manida Suksawat & Sureerat Padthaisong
Pages: 985-1006
Published online: 22 Jul 2021
AbstractforTherapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma | Full Text | References | PDF (3.2 MB) | EPUB
  • 218 Views
  • 1 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs
Lorenza Magagnoli et al.
Review Article | Published online: 19 Jun 2024
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka et al.
Review Article | Published online: 18 Jun 2024
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development
Luca Iorio et al.
Report | Published online: 16 Jun 2024
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol
Amanda J. Hooper et al.
Editorial | Published online: 15 Jun 2024
Free Access
View all latest articles